HanchorBio Participating in the J.P. Morgan Healthcare Conference 2026
As the holiday season approaches, HanchorBio is kicking off 2026 with active engagement at one of the industry’s most important global healthcare events. HanchorBio is participating in the J.P. Morgan Healthcare Conference 2026, held January 12–15, 2026, in San Francisco.
During the conference, Scott Liu, PhD, Founder, Chairman, and CEO, Alvin Luk, PhD, MBA, President & Chief Medical Officer (Group) and Chief Executive Officer (U.S.), together with Yuehua Cong, PhD, Chief Business Officer, are on site meeting with global partners, investors, and industry leaders to discuss collaboration opportunities and HanchorBio’s strategic growth.
HanchorBio is advancing next-generation innate-immunity biologics aimed at transforming cancer immunotherapy, including:
-
HCB101, a next-generation CD47–SIRPα fusion protein designed as an innate-immune backbone for combination therapies with PD-1 inhibitors, anti-VEGF agents, HER2-targeted therapies, EGFR inhibitors, antibody–drug conjugates (ADCs), and radiotherapy
-
HCB301, a tri-specific SIRPα–PD-L1–TGFβ fusion protein designed to reprogram macrophage and T-cell biology
-
FBDB™, HanchorBio’s multi-specific protein engineering platform, enabling programmable immune re-balancing across multiple tumor types
Through innovative science and platform-driven development, HanchorBio remains committed to transforming immunotherapy and advancing health for all.
漢康生技參與 2026 年 摩根大通健康醫療大會
隨著年末佳節將至，漢康生技以積極的產業交流揭開 2026 年序幕。漢康生技現正參與 2026 年摩根大通健康醫療大會，活動於 2026 年 1 月 12 日至 15 日在美國舊金山舉行。
大會期間，漢康生技創辦人、董事長暨執行長劉世高博士、集團總裁暨首席醫學長、以及美國區執行長陸英明博士，與 商務長叢越華博士正與全球合作夥伴、投資人及產業領袖進行交流，深入探討策略合作與公司未來布局。
漢康生技專注於推動 新一代先天免疫（Innate Immunity）生物藥的研發，核心研發項目包括：
-
HCB101：新一代 CD47–SIRPα 融合蛋白，可作為先天免疫治療骨幹，應用於與 PD-1 抑制劑、抗 VEGF 藥物、HER2 標靶治療、EGFR 抑制劑、抗體藥物複合體（ADC）及放射治療之聯合療法
-
HCB301：具備 SIRPα–PD-L1–TGFβ 三重靶點的融合蛋白，旨在重塑巨噬細胞與 T 細胞的免疫調控機制
-
FBDB™ 多特異性蛋白工程平台：可跨不同腫瘤類型實現可程式化的免疫再平衡
漢康生技透過創新科學與平台導向研發，持續致力於 革新免疫治療，促進全民健康。
